

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6419985

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	REAFFIRMED AND AMENDED SECURITY INTEREST (TERM)
CONVEYING PARTY DATA	
Name	Execution Date
SIGHT SCIENCES, INC.	11/23/2020
RECEIVING PARTY DATA	
Name:	MIDCAP FINANCIAL TRUST, AS AGENT
Street Address:	7255 WOODMONT AVE., SUITE 200
City:	BETHESDA
State/Country:	MARYLAND
Postal Code:	20814
PROPERTY NUMBERS Total: 35	
Property Type	Number
Patent Number:	7909789
Patent Number:	8287482
Patent Number:	9370443
Patent Number:	9486361
Patent Number:	10314742
Patent Number:	10398597
Patent Number:	8529622
Patent Number:	8439972
Patent Number:	8876898
Patent Number:	10406030
Patent Number:	9095412
Patent Number:	9216109
Patent Number:	9855167
Patent Number:	8894603
Patent Number:	9895258
Patent Number:	10179066
Patent Number:	10299958
Patent Number:	9510972
Patent Number:	9844459
Patent Number:	10052226

PATENT

Property Type	Number
Patent Number:	9724230
Patent Number:	10772758
Patent Number:	9642743
Application Number:	16413466
Application Number:	16526832
Application Number:	14973620
Application Number:	15854126
Application Number:	16189882
Application Number:	16397733
Application Number:	16943644
Application Number:	16059281
Application Number:	15374426
Application Number:	16127870
PCT Number:	US2012059384
Application Number:	16532260

CORRESPONDENCE DATA

Fax Number: (703)610-6200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7036106100

Email: boxip@hoganlovells.com

Correspondent Name: GRETA D. FELDMAN OF HOGAN LOVELLS US LLP

Address Line 1: 8350 BROAD STREET, 17TH FLOOR

Address Line 2: ATTN: BOX INTELLECTUAL PROPERTY

Address Line 4: TYSONS, VIRGINIA 22102

ATTORNEY DOCKET NUMBER:	036639.000090
NAME OF SUBMITTER:	GRETA D. FELDMAN OF HOGAN LOVELLS US LLP
SIGNATURE:	/Greta D. Feldman/
DATE SIGNED:	11/25/2020

Total Attachments: 10

- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page1.tif
- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page2.tif
- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page3.tif
- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page4.tif
- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page5.tif
- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page6.tif
- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page7.tif
- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page8.tif
- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page9.tif
- source=MidCap_Sight Sciences Reaffirmation Agreement - Term - Patents#page10.tif

**REAFFIRMATION AGREEMENT AND AMENDMENT TO INTELLECTUAL PROPERTY
SECURITY AGREEMENT**

This **REAFFIRMATION AGREEMENT AND AMENDMENT TO INTELLECTUAL PROPERTY SECURITY AGREEMENT** (this “**Agreement**”) is made as of this 23rd day of November, 2020, by and among **SIGHT SCIENCES, INC.**, a Delaware corporation (the “**Obligor**”) and **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, as agent (in such capacity, together with its successors and permitted assigns, “**Agent**”) for the Lenders party to the Amended and Restated Credit Agreement (defined below). All capitalized terms used but not elsewhere defined herein shall have the respective meanings ascribed to such terms in the Amended and Restated Credit Agreement.

W I T N E S S E T H:

A. The Obligor, Agent and the Lenders party thereto have entered into that certain Credit and Security Agreement (Term Loan), dated as of January 25, 2019 (as amended, supplemented, or otherwise modified from time to time prior to the date hereof, the “**Existing Credit Agreement**”), pursuant to which the Lenders party thereto made loans and other financial accommodations to the Borrowers (as defined in the Existing Credit Agreement), subject to the terms and conditions set forth therein.

B. In connection with the Existing Credit Agreement, the Obligor has previously reviewed, consented to and, if applicable, executed various agreements, documents and instruments in connection with the Existing Credit Agreement, including, without limitation, all Financing Documents (excluding the Existing Credit Agreement and any separate fee letters) in effect immediately prior to giving effect to the Closing Date (collectively, the “**Existing Financing Documents**”).

C. The Obligor, Agent and the Lenders party thereto have agreed to amend and restate the Existing Credit Agreement in its entirety, without constituting a novation, pursuant to that certain Amended and Restated Credit and Security Agreement (Term Loan) of even date herewith (as the same may be amended, restated, supplemented or otherwise modified from time to time, the “**Amended and Restated Credit Agreement**”) by and among the Obligor, Agent and the Lenders party thereto.

D. Obligor shall derive both direct and indirect benefits from the loans and other financial accommodations made pursuant to the provisions of the Amended and Restated Credit Agreement.

E. One of the conditions precedent to Agent and the Lenders entering into the Amended and Restated Credit Agreement is that the Obligor execute and deliver this Agreement, among other things, to acknowledge and agree that the Existing Financing Documents, and the liens, security interests granted and issued thereunder, secure the Obligations.

NOW, THEREFORE, in consideration of the premises set forth herein and for other good and valuable consideration, the receipt and sufficiency of which hereby are acknowledged, each of the undersigned hereby agrees as follows:

1. References Contained in the Existing Financing Documents. All references in the Existing Financing Documents to the “**Obligations**” to Agent and the Lenders shall be deemed to refer to, without limitation, the “**Obligations**” of the Obligor under, pursuant to and as defined in the Amended and Restated Credit Agreement. All references in the Existing Financing Documents to the “**Credit Agreement**” shall be deemed to refer to the Amended and Restated Credit Agreement. All references in

the Existing Financing Documents to the “Lenders” (or words of similar import) shall be deemed to refer to the Lenders under the Amended and Restated Credit Agreement.

2. Reaffirmation. In connection with the execution and delivery of the Amended and Restated Credit Agreement, the Obligor, as borrower, debtor, grantor, pledgor or assignor, as applicable, or in any other similar capacities in which such Person grants Liens or security interests in its property, as the case may be, in any case under the Existing Financing Documents, including without limitation each document to which the Obligor is a party thereto set forth on Schedule A hereto, hereby to the extent the Obligor granted Liens on or security interests in any of its property pursuant to any such Existing Financing Documents as security for the Obligations, ratifies and reaffirms such grant of security and confirms and agrees that such Liens and security interests hereafter secure all of the Obligations under the Existing Financing Documents, as amended hereby and as amended by the Amended and Restated Credit Agreement and the other Financing Documents, in each case including, without limitation, all obligations, indebtedness and liabilities resulting from the Amended and Restated Credit Agreement, and as if each reference in such Existing Financing Documents, as amended hereby and as amended by the Amended and Restated Credit Agreement and the other Financing Documents, to the obligations, indebtedness and liabilities secured thereby are construed hereafter to mean and refer to such obligations, indebtedness and liabilities under the Amended and Restated Credit Agreement and the other Financing Documents, including, without limitation, the Existing Financing Documents, as amended hereby and as amended by the Amended and Restated Credit Agreement and the other Financing Documents.

The Obligor acknowledges receipt of a copy of the Amended and Restated Credit Agreement and the Financing Documents executed and delivered in connection therewith and acknowledges that each of the Existing Financing Documents, as amended hereby and as amended by the Amended and Restated Credit Agreement and the other Financing Documents, remains in full force and effect and hereby is ratified and confirmed. The execution and delivery of this Agreement, and the performance of the Obligor’s obligations hereunder, shall not (i) operate as a waiver of any right, power or remedy of Agent or the Lenders, (ii) constitute a waiver of any provision of any of the Existing Financing Documents, or (iii) constitute a novation of any of the Obligations under the Existing Credit Agreement or the Financing Documents (including, without limitation, the Existing Financing Documents). The Obligor agrees that this Agreement constitutes a “Financing Document” under the Amended and Restated Credit Agreement.

3. Representations and Warranties and Amendments to the Intellectual Property Security Agreement Exhibits.

(a) The Obligor hereby confirms to Agent that the representations and warranties set forth in the Existing Financing Documents (excluding the Existing Credit Agreement), as amended by this Agreement, made by the Obligor are true and correct in all material respects on and as of the date hereof as if such representation or warranty were made on and as of the date hereof; provided, however, that (A) such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof and (B) those representations and warranties expressly referring to a specific date shall be true, correct and complete in all material respects as of such date. The Obligor hereby represents and warrants to Agent that: (i) such Person has the power and is duly authorized to enter into, deliver and perform this Agreement; (ii) upon the execution and delivery hereof, this Agreement shall be valid, binding and enforceable upon such Person in accordance with its terms (except as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other similar laws relating to or affecting creditors’ rights generally); (iii) Agent has and shall continue to have, to the extent required by the Amended and Restated Credit Agreement, valid, enforceable and perfected first-priority liens, subject to Permitted Liens, on and security interests in the Collateral and all other collateral heretofore granted by the Obligor to Agent, for the benefit of Agent and

each Lender, pursuant to the Financing Documents, the Existing Financing Documents or otherwise granted to or held by Agent, for the benefit of Agent and each Lender and (iv) no Default or Event of Default has occurred and is continuing.

(b) In connection herewith, the parties hereto desire to amend and restate the exhibits to that certain Intellectual Property Security Agreement (Term Loan), dated as of January 25, 2019 (as the same has been amended, restated, supplemented or otherwise modified, the “IPSA”) among Obligor and Agent in their entirety without constituting a novation. The Obligor hereby represents and warrants to Agent, for the benefit of the Lenders, that such exhibits attached hereto as Exhibit A, Exhibit B, Exhibit C and Exhibit D accurately and completely set forth the information required pursuant to the IPSA as of the date hereof, and, notwithstanding anything to the contrary set forth herein, references in the IPSA to information in the exhibits being “as of the Closing Date” (or words of similar import) shall mean as of the date hereof. Delivery of such disclosures shall not relieve or otherwise constitute a waiver by Agent or any Lender or a cure of any Default or Event of Default under the Existing Credit Agreement resulting in connection with the matters disclosed or a breach of the underlying covenant, representation or warranty (regardless of such disclosure).

4. No Further Amendments; Ratification of Liability; Effect. Except as amended hereby, each of the Existing Financing Documents (excluding the Existing Credit Agreement) shall remain in full force and effect in accordance with their respective terms. The Obligor hereby ratifies and confirms its liabilities, obligations and agreements under the Existing Financing Documents (excluding the Existing Credit Agreement), all as amended by this Agreement, and acknowledges that (i) the Obligor, to the best of its knowledge, has no defenses, claims or set-offs to the enforcement by Agent of such liabilities, obligations and agreements, (ii) Agent and the Lenders have fully performed all obligations to such Persons which Agent and the Lenders may have had or have on and as of the date hereof and (iii) neither Agent nor any of the Lenders waives, diminishes or limits any term, condition or covenant contained in the Existing Financing Documents (excluding the Existing Credit Agreement).

5. Successors and Assigns. This Agreement shall be binding upon the Obligor and its successors and assigns and shall inure to the benefit of Agent and the Lenders and their respective successors and assigns; all references herein to the Obligor shall be deemed to include its respective successors and assigns. The successors and assigns of such Persons shall include, without limitation, their respective receivers, trustees or debtors-in-possession.

6. Further Assurances. The Obligor hereby agrees from time to time, as and when reasonably requested by Agent, to execute and deliver or cause to be executed and delivered (or otherwise authorized), all such documents, instruments and agreements, including, without limitation, any UCC financing statements (including, without limitation, any initial financing statements or in lieu financing statements), and to take or cause to be taken such further or other action as Agent may reasonably deem necessary in order to carry out the intent and purposes of this Agreement, the Amended and Restated Credit Agreement and the other Financing Documents, in each case as amended hereby.

7. Definitions. All references to the singular shall be deemed to include the plural and vice versa where the context so requires.

8. Governing Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES (OTHER THAN SECTION 5-1401 OF THE GENERAL OBLIGATIONS LAW).

9. Waiver of Jury Trial. THE OBLIGOR AND AGENT HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY AND AGREES THAT ANY SUCH ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY. THE OBLIGOR AND AGENT ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS RELIED ON THE WAIVER IN ENTERING INTO THIS AGREEMENT, AND THAT EACH WILL CONTINUE TO RELY ON THIS WAIVER IN THEIR RELATED FUTURE DEALINGS. THE OBLIGOR AND AGENT WARRANTS AND REPRESENTS THAT IT HAS HAD THE OPPORTUNITY OF REVIEWING THIS JURY WAIVER WITH LEGAL COUNSEL, AND THAT IT KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS.

10. Indemnification. The Obligor acknowledges its indemnification obligations pursuant to Section 11.6 of the Amended and Restated Credit Agreement.

11. Severability. Wherever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective to the extent of such prohibition or invalidity without invalidating the remainder of such provision or the remaining provisions of this Agreement.

12. Entire Agreement. This Agreement embodies the entire agreement between the parties hereto relating to the subject matter hereof and supersedes all prior agreements, representations and understandings, if any, relating to the subject matter thereof.

13. Execution in Counterparts. This Agreement may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission shall be as effective as delivery of a manually executed counterpart hereof. Delivery of an executed counterpart of this Agreement by facsimile or by electronic mail delivery of an electronic version (e.g., .pdf or .tif file) of an executed signature page shall be effective as delivery of an original executed counterpart hereof and shall bind the parties hereto.


14. Section Headings. The section headings herein are for convenience of reference only, and shall not affect in any way the interpretation of any of the provisions hereof.

[Remainder of page intentionally left blank; signature pages follow]

IN WITNESS WHEREOF, this Agreement has been duly executed by each of the undersigned as of the day and year first set forth above.

OBLIGOR:

SIGHT SCIENCES, INC.


By: 
Name: Jesse Selnick
Title: CFO

AGENT:

MIDCAP FINANCIAL TRUST, as Agent

By: Apollo Capital Management, L.P.,
its investment manager

By: Apollo Capital Management GP, LLC,
its general partner

By:  _____

Name: Maurice Amsellem
Title: Authorized Signatory

SCHEDULE A

1. Intellectual Property Security Agreement (Term Loan), dated as of January 25, 2019, by and among the Obligor and Agent, as amended, restated, supplemented or otherwise modified from time to time.

EXHIBIT B

Patents

Country	Application No.	Application Date	Publication No.	Publication Date	Registration No.	Registration Date	Case Status
INTRAOcular IMPLANTS AND METHODS AND KITS THEREFOR							
CH	07777368.7	5/31/2007			2034937	7/11/2012	Registered
DE	07777368.7	5/31/2007			2034937	7/11/2012	Registered
EPO	07777368.7	5/31/2007	2034937	3/18/2009	2034937	7/11/2012	EP Granted
EPO	11162487.0	5/31/2007	2338445	6/29/2011			Abandoned
ES	07777368.7	5/31/2007			2034937	7/11/2012	Registered
FR	07777368.7	5/31/2007			2034937	7/11/2012	Registered
GB	07777368.7	5/31/2007			2034937	7/11/2012	Registered
IT	07777368.7	5/31/2007			2034937	7/11/2012	Registered
JP	2009-518132	5/31/2007	2009-541005	11/26/2009	5520600	4/11/2014	Registered
JP	2012-235335	5/31/2007	2013-17836	1/31/2013			Abandoned
JP	2014-152575	5/31/2007	2014-198268	10/23/2014	6113118	3/24/2017	Registered
PCT	PCT/US2007/013038	5/31/2007	WO/2008/002377	1/3/2008			Expired/PCT Period Over
US	11/475,523	6/26/2006	US 2007-0298068	12/27/2007	7,909,789	3/22/2011	Registered
US	12/695,053	1/27/2010	US 2010-0191329	7/29/2010	8,287,482	10/16/2012	Registered
US	13/025,112	2/10/2011	US 2011-0130831	6/2/2011	9,370,443	6/21/2016	Registered
US	13/445,816	4/12/2012	US 2012-0197176	8/2/2012	9,486,361	11/8/2016	Registered
US	15/182,165	6/14/2016	US 2016-0287440	10/6/2016	10,314,742	6/11/2019	Registered
US	15/340,911	11/1/2016	US 2017-0143541	5/25/2017	10,398,597	9/3/2019	Registered
US	16/413,466	5/15/2019	US 2020-0038243	2/6/2020			Pending
US	16/526,832	7/30/2019	US 2020-0121503	4/23/2020			Pending
INTRAOcular IMPLANTS AND RELATED KITS AND METHODS							
DE	11740372.5	2/3/2011	2531138		2531138	11/30/2016	Registered
EPO	11740372.5	2/3/2011	2531138	12/12/2012	2531138	11/30/2016	EP Granted
FR	11740372.5	2/3/2011	2531138		2531138	11/30/2016	Registered
GB	11740372.5	2/3/2011	2531138		2531138	11/30/2016	Registered
JP	2012-552089	2/3/2011	2013-518679	5/23/2013	5856569	12/18/2015	Registered
JP	2015-23027	2/3/2011	2015-91431	5/14/2015			Abandoned
PCT	PCT/US2011/023643	2/3/2011	WO/2011/097408	8/11/2011			Expired/PCT Period Over
US	61/301,874	2/5/2010					Expired
US	13/020,706	2/3/2011	US 2011-0196487	8/11/2011	8,529,622	9/10/2013	Registered
US	13/245,811	9/26/2011	US 2012-0059461	3/8/2012	8,439,972	5/14/2013	Registered
US	14/012,963	8/28/2013	US 2013-0345808	12/26/2013	8,876,898	11/4/2014	Registered
US	14/527,292	10/29/2014	US 2015-0051699	2/19/2015			Abandoned
US	15/343,147	11/3/2016	US 2017-0202707	7/20/2017			Abandoned
US	15/683,652	8/22/2017	US 2017-0348152	12/7/2017	10,406,030	9/10/2019	Registered
US	16/532,260	8/5/2019	US 2020-0129333	4/30/2020			Pending
OCULAR DELIVERY SYSTEMS AND METHODS							
AU	2018200231	10/4/2012			2018200231	5/14/2020	Registered
AU	2012374034	10/4/2012			2012374034	2/1/2018	Registered
AU	2020202716	10/4/2012					Pending
BR	BR112015000941-7	10/4/2012					Abandoned
CA	2878271	10/4/2012					Pending

EPO	16155079.3	10/4/2012	3047823	7/27/2016			Pending
EPO	12871982.0	10/4/2012	2844200	3/11/2015			Allowed
JP	2015-527438	10/4/2012					Abandoned
PCT	PCT/US2012/058751	10/4/2012	WO/2013/141898	9/26/2013			Expired/PCT Period Over
US	61/613,274	3/20/2012					Expired
US	13/644,748	10/4/2012	US 2013-0253437	9/26/2013	9,095,412	8/4/2015	Registered
US	13/644,758	10/4/2012	US 2013-0253438	9/26/2013	9,216,109	12/22/2015	Registered
US	13/644,769	10/4/2012	US 2013-0253402	9/26/2013	9,855,167	1/2/2018	Registered
US	13/644,780	10/4/2012	US 2013-0253403	9/26/2013	8,894,603	11/25/2014	Registered
US	14/539,648	11/12/2014	US 2015-0073328	3/12/2015	9,895,258	2/20/2018	Registered
US	14/816,822	8/3/2015	US 2015-0335481	11/26/2015	10,179,066	1/15/2019	Registered
US	14/973,620	12/17/2015	US 2016-0100980	4/14/2016			Pending
US	15/854,126	12/26/2017	US 2018-0271699	9/27/2018			Pending
US	16/189,882	11/13/2018	US 2019-0142632	5/16/2019			Allowed
OCULAR DELIVERY SYSTEMS AND METHODS							
AU	2015390071	3/31/2015					Pending
CA	2980713	3/31/2015					Pending
CN	201580079974.6	3/31/2015	CN 107530190 A	1/2/2018			Pending
EPO	15888007.0	3/31/2015	3277236	2/7/2018			Pending
HK	18109217.8	3/31/2015	1249726	11/9/2018			Pending
JP	2017-505632	3/31/2015	2018-513696	5/31/2018	6652961	1/28/2020	Registered
JP	2020-9776	3/31/2015	2020-58915	4/16/2020			Pending
PCT	PCT/US2015/023720	3/31/2015	WO 2016/159999	10/6/2016			Expired/PCT Period Over
US	14/675,580	3/31/2015	US 2016-0287438	10/6/2016	10,299,958	5/28/2019	Registered
US	16/397,733	4/29/2019	US 2019-0314200	10/17/2019			Pending
SYSTEMS AND METHODS FOR DELIVERING FLUID TO THE SUPRACHOROIDAL SPACE							
US	62/880,551	7/30/2019					Expired
US	62/907,472	9/27/2019					Abandoned
US	16/943,644	7/30/2020					Pending
OCULAR DELIVERY SYSTEMS AND METHODS							
US	62/907,474	9/27/2019					Expired
DRY EYE TREATMENT SYSTEMS							
BRAZIL	BR 11 2014 016505 0	10/9/2012	2423				PUBLISHED
CHINA	2012800711619	10/9/2012	CN 104334129 A		ZL 2012800711619		ISSUED
CHINA	2017107693584	10/9/2012	CN 107510545 A				PUBLISHED
EP	12865218.8	10/9/2012	2800543				PUBLISHED
JAPAN	2014-551238	10/9/2012	2015-503417				PUBLISHED
JAPAN	2018-193884	10/9/2012					PENDING
PCT	PCT/US2012/059384	10/9/2012	WO2013/103413 A1				NAT PHASE
US	13/645,985	10/5/2012	US-2013-0172829- A1		9,510,972		ISSUED
US	13/364,070	11/29/2016	US-2017-0079834- A1		9,844,459		ISSUED
US	15/442,003	2/24/2017	US-2017-0165106- A1		10,052,226		ISSUED
US	16/059,281	8/9/2018	US-2018-0344512- A1				PUBLISHED
DRY EYE TREATMENT APPARATUS AND METHODS							

US	13/343,407	1/4/2012	US-2013-0172790-A1		9,724,230		ISSUED
US	15/639,850	6/30/2017	US-2017-0304110-A1		10,772,758	9/15/2020	ISSUED
CONTROLLER FOR DRY EYE TREATMENT SYSTEMS							
US	14/967,116	12/11/2015	US-2016-0106576-A1		9,724,230	8/8/2017	ISSUED
METHODS FOR IMPROVING CONTACT LENS COMFORT							
US	15/369,176	12/5/2016	US-2017-0079840-A1		9,642,743	5/9/2017	ISSUED
COMBINATION TREATMENT SYSTEMS							
US	15/374,426	12/9/2016	US-2017-0087009-A1				PUBLISHED
PCT	PCT/US2016/065876	12/9/2016	WO 2017/10068				ABANDONED
FORCEPS TREATMENT SYSTEMS							
US	16/127,870	9/11/2018	20200078211				PUBLISHED
FORCEPS FOR DRY EYE TREATMENTS							
US	62/266,483	12/11/2015					EXPIRED